Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
The doctor holds the results of the examination of a patient with intestinal inflammation and abdominal pain.
Though Crohn’s disease and ulcerative colitis have similar symptoms and unknown causes, they affect disparate parts of the GI tract and require different therapies.

Novel Model Could Make IBD Tests Less Invasive

Glycosylation on antibodies may accurately detect and differentiate Crohn’s and ulcerative colitis

American Chemical Society
Published:Sep 08, 2023
|2 min read
Register for free to listen to this article
Listen with Speechify

Millions of Americans have inflammatory bowel disease (IBD), which occurs in one of two forms: Crohn’s disease or ulcerative colitis (UC). Though the two have similar symptoms, they require different treatment strategies, and tests to distinguish between them are invasive. Reporting in ACS’ Journal of Proteome Research, researchers show that chains of sugar molecules are tacked onto antibodies differently in patients with the diseases, which could someday lead to a simple blood-based diagnostic test.

Though Crohn’s disease and UC have similar symptoms and unknown causes, they affect disparate parts of the GI tract and, therefore, require different therapies. Currently, distinguishing between the two typically requires invasive procedures, such as an endoscopy or biopsy. To develop a less uncomfortable option, some researchers are exploring biomarkers in blood or other easily accessible body fluids. 

Antibodies could serve as biomarkers, given that immunoglobulin G (IgG) was previously shown to play a role in autoimmune diseases, including IBD. But another class, immunoglobulin A (IgA), could play a role as well, because it functions within the mucous membranes that cover and protect internal organs, such as the intestinal tract. 

These immune molecules can be decorated with chains of sugars, called glycans, and this can affect their structure and function. Since Crohn’s disease and UC both affect the intestinal tract, Manfred Wuhrer, PhD, and colleagues wanted to understand how IgA glycosylation might differ between these two diseases.

To investigate these glycosylation patterns, the researchers analyzed over 400 clinical plasma samples from patients with either form of IBD, and around 200 healthy controls. Using a combination of liquid chromatography and mass spectrometry, they found over 30 different forms of the IgA1 and IgA2 antibodies. 

The glycans differed between the three experimental groups: The Crohn’s disease patients had IgAs with fewer branched sugars, but more glycosylation overall compared to other groups. UC patients had more glycans attached to the opposite end of the IgA protein chain than the control group. 

These patterns were used to construct a preliminary statistical model that could predict the disease group, and the model could be expanded further to be used as a diagnostic tool. The researchers say that this work could help make diagnosing IBD easier and less invasive for patients.

- This press release was originally published on the American Chemical Society website